Latest Posts
About This Stock
More About This Stock
Read
Read
Read
Read
Week In Review: Chi-Med Plans $500 Million Hong Kong IPO
Article By:
ChinaBio® Today
Saturday, April 20, 2019 4:48 PM EST
Hutchison China MediTech filed to IPO on the Hong Kong Exchange, following listings in London and on NASDAQ, where it has a market capitalization of over $4 billion. The IPO is expected to raise between $300 million and $500 million.
Week In Review: Inventis Closes $70 Million Financing To Develop 30 Novel Therapeutics
Article By:
ChinaBio® Today
Saturday, March 16, 2019 4:22 PM EST
InventisBio of Shanghai closed a $70 million Series C financing led by Advantech Capital and CMBI, followed by Pudong Innotek. Founded in 2013, InventisBio focuses on discovering and developing novel therapeutics for cancer and metabolic diseases.
Week In Review: Grifols Pays $1.9 Billion For 26% Stake In Shanghai RAAS
Article By:
ChinaBio® Today
Saturday, March 9, 2019 4:13 PM EST
Grifols, a Barcelona maker of plasma-based medicines, acquired a 26% stake in Chinese blood plasma company Shanghai RAASfor $1.9 billion in a non-cash deal. Grifols will exchange a 45% ownership in Grifols Diagnostic Solutions for the RAAS stake.
Week In Review: China Pharmas Announce Deals Worth $1.5 Billion
Article By:
ChinaBio® Today
Saturday, December 8, 2018 4:21 PM EST
WuXi AppTec, China's largest CRO/CMO, completed a $1 billion IPO on the Hong Kong markets, pricing the offering in the middle of the expected range (see story). In May, WuXi became a public company by completing a $328 million IPO in Shanghai.